GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Casimersen - AMONDYS 45 intravenous injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

AMONDYS 45 / casimersen

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

A creatinine-only dosing shortcut is inappropriate for this evidence

The product requires DMD-specific renal surveillance rather than a validated creatinine-based reduction table.

Before applying: Use the dated monitoring card, including urine-collection timing and assay interference precautions; do not infer a renal dose.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

AMONDYS 45 - casimersen injection

Product / population
AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.
Renal measure
DMD monitoring: cystatin C, urine protein and optional measured GFR; no validated eGFR-based adjustment

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Renal dosing, restrictions and evidence limits

Before treatment measure cystatin C, urine dipstick and urine protein-to-creatinine ratio; consider measured GFR using an exogenous filtration marker. Reduced muscle mass makes creatinine unreliable in DMD.

Check urine dipstick monthly and cystatin C/protein-to-creatinine ratio every three months. Collect urine before an infusion or at least 48 hours afterward; alternatively use a protein assay without pyrogallol red to avoid drug-related false positivity. Persistent cystatin C elevation or proteinuria warrants pediatric-nephrology evaluation.

The renal study in non-DMD adults cannot establish an eGFR-based adjustment for DMD. Section 8.6 provides no specific adjustment recommendation and calls for closer monitoring in known impairment.

Source revision: 1/2026 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9e5fd44-eeda-4580-bba1-a734828bbcc3

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

AMONDYS 45 - casimersen injection

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - AMONDYS 45

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

AMONDYS 45 - casimersen injection

Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Dialysis evidence: No dialysis regimen established in selected content

AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

Renal method: DMD monitoring: cystatin C, urine protein and optional measured GFR; no validated eGFR-based adjustment
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - AMONDYS 45

Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Dialysis evidence: No dialysis regimen established in selected content

AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

Renal method: DMD-specific monitoring; creatinine alone may be unreliable
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A creatinine-only dosing shortcut is inappropriate for this evidence

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population specific monitoring

A creatinine-only dosing shortcut is inappropriate for this evidence

The product requires DMD-specific renal surveillance rather than a validated creatinine-based reduction table.

How to use this: Use the dated monitoring card, including urine-collection timing and assay interference precautions; do not infer a renal dose.

GlobalRPh RX List - AMONDYS 45AMONDYS 45 - casimersen injection

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

AMONDYS 45 - casimersen injection

AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

Method: DMD monitoring: cystatin C, urine protein and optional measured GFR; no validated eGFR-based adjustment

Renal dosing, restrictions and evidence limitsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAMONDYS 45 - casimersen injectionGlobalRPh RX List - AMONDYS 45
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/amondys-45-drug/

Exact product and population

AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

RDM58-SCOPE-casimersen-amondys45 · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

AMONDYS 45 - casimersen injection

Open original reference

Open / share this exact local source

DailyMed / Sarepta Therapeutics, Inc. · AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

Renal method: DMD monitoring: cystatin C, urine protein and optional measured GFR; no validated eGFR-based adjustment
Source date: 1/2026
Retrieved: 2026-09-10

Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Before treatment measure cystatin C, urine dipstick and urine protein-to-creatinine ratio; consider measured GFR using an exogenous filtration marker. Reduced muscle mass makes creatinine unreliable in DMD.

Check urine dipstick monthly and cystatin C/protein-to-creatinine ratio every three months. Collect urine before an infusion or at least 48 hours afterward; alternatively use a protein assay without pyrogallol red to avoid drug-related false positivity. Persistent cystatin C elevation or proteinuria warrants pediatric-nephrology evaluation.

The renal study in non-DMD adults cannot establish an eGFR-based adjustment for DMD. Section 8.6 provides no specific adjustment recommendation and calls for closer monitoring in known impairment.

RDM58-official-casimersen-amondys45-148a680973-C1 · Source locator: Sections 2.2, 5.2 and 8.6

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9e5fd44-eeda-4580-bba1-a734828bbcc3
Retrieved
2026-09-10
Exact label title
AMONDYS 45 - casimersen injection
DailyMed Set ID
e9e5fd44-eeda-4580-bba1-a734828bbcc3
Labeler
Sarepta Therapeutics, Inc.
DailyMed page updated
2026-01-09
Label revision
1/2026
Renal-function method
DMD monitoring: cystatin C, urine protein and optional measured GFR; no validated eGFR-based adjustment
Source date/version
1/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
794ba590bc11a3f66463be5e2d6bbad5cc1627994a5b08e9140ab80f18dad9cb
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - AMONDYS 45

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.

Renal method: DMD-specific monitoring; creatinine alone may be unreliable
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror warns about animal kidney toxicity and the kidney risks observed with some antisense oligonucleotides. Monitoring remains necessary even though kidney toxicity was not observed in the cited AMONDYS 45 clinical studies.

Reduced skeletal muscle mass can make creatinine-based assessment unreliable in DMD. The selected renal evidence does not establish a patient-specific clearance-band reduction or a dialysis supplement; use the separately dated official monitoring card for the checked surveillance details.

RDM58-rxlist-casimersen-amondys45-32ffe17747-C1 · Source locator: Warnings: Kidney Toxicity; Renal Impairment

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/amondys-45-drug/
Retrieved
2026-09-10
Renal-function method
DMD-specific monitoring; creatinine alone may be unreliable
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ddfc08045b03670feff30a4851b4ccdc53cecaeab336e12c62c4f63d42c96ce5

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/amondys-45-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
5fa1c9b4fef058331699e0365edc589b4e7ec6a87403f4191f2d0d948c5883f5
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report